Current News - U.S.
-
Boehringer Ingelheim Earns Top Marks In 2009 Corporate
Equality Index - TRANSCEND™ Trial Results Presented at European Society of Cardiology Congress and Published in The Lancet
- New Aptivus® (tipranavir) Oral Solution Approved for Treatment-Experienced Pediatric and Adolescent HIV Patients
- PRoFESS® Results Announced at XVII European Stroke Conference
- Boehringer Ingelheim Committed to Advancing the Science of Hypoactive Sexual Desire Disorder
- Second Chances Study Shows Most Stroke Survivors “Very Satisfied” with their Overall Quality of Life
- Landmark ONTARGET™ trial demonstrates Micardis® is equally effective as ramipril, with fewer discontinuations, in a broad high-risk cardiovascular population
- View more Current News : : View the News Archive
BI Spotlight
Boehringer Ingelheim Earns Top Marks In 2009 Corporate Equality Index
Ridgefield, CT - September 2, 2008 --
Boehringer Ingelheim proudly announced that it has earned the top rating of 100 percent in the 2009 Corporate Equality Index (CEI), an annual survey administered by the Human Rights Campaign Foundation.
Product Sites
Job Openings
Our Locations
R&D
